newsfilter
← Latest News
PR Newswire·

Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea

ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting that researchers have demonstrated the